Table 2.
Patient demographics and baseline clinical characteristics
| Control (n = 90) | Remdesivir (n = 82) | Sotrovimab (n = 88) | P | |
|---|---|---|---|---|
| Age (years), mean (SD) | 55.2 (16.8) | 58 (14.2) | 55.8 (12.5) | 0.42 |
| Female, n (%) | 44 (49) | 45 (54.9) | 44 (50) | 0.71 |
| Race, n (%) | ||||
| Caucasian | 55 (61) | 51 (62.2) | 59 (67) | 0.68 |
| African American | 20 (22.3) | 15 (18.3) | 11 (12.5) | 0.23 |
| Hispanic | 14 (15.6) | 6 (7.3) | 4 (4.5) | 0.03 |
| other | 1 (1.1) | 10 (12.2) | 14 (15.9) | 0.006 |
| BMIa, mean (SD) | 30.8 (7.9) | 31.6 (7.3) | 29.8 (6.5) | 0.29 |
| Risk factors for severe COVID-19, n (%) | ||||
| ≥65 years | 31 (34.4) | 33 (40.2) | 22 (25) | 0.1 |
| BMIa ≥35 | 25 (27.8) | 27 (32.9) | 16 (18.2) | 0.08 |
| diabetes | 37 (41.2) | 38 (46.3) | 28 (32) | 0.14 |
| chronic kidney disease | 23 (25.6) | 25 (30.5) | 40 (45.5) | 0.014 |
| hypertension | 66 (73.4) | 55 (67.1) | 58 (66) | 0.52 |
| cardiovascular disease | 36 (40) | 20 (24.4) | 12 (13.6) | 0.0003 |
| chronic lung disease | 17 (18.9) | 22 (26.8) | 21 (23.9) | 0.46 |
| immunocompromised | 66 (73.3) | 53 (64.6) | 81 (92) | 0.00008 |
| pregnant | 2 (2.3) | 0 (0) | 0 (0) | 0.87 |
| unvaccinated | 31 (34.4) | 14 (17) | 21 (23.9) | 0.03 |
| total risk factors, mean (SD) | 4.1 (1.3) | 3.9 (1.4) | 3.7 (1.6) | 0.17 |
| Initial vaccine series completed, n (%) | 59 (65.6) | 68 (83) | 67 (76.1) | 0.03 |
| BNT162b2 (Pfizer-BioNTech) | 33 (56) | 39 (57.3) | 50 (74.6) | 0.05 |
| mRNA-1273 (Moderna) | 19 (32) | 23 (33.8) | 14 (20.9) | 0.2 |
| Ad26.COV2.S (Johnson & Johnson) | 2 (3) | 1 (1.5) | 0 (0) | 0.92 |
| unknown | 5 (9) | 5 (7.4) | 3 (4.5) | 0.65 |
| time from completed initial vaccine series to positive test (days), mean (SD) | 274.5 (77.1) | 271.8 (79.9) | 291.7 (57.4) | 0.26 |
| Booster dose received, n (%) | 32 (35.6) | 36 (43.9) | 43 (48.9) | 0.18 |
| time from booster dose to positive test (days), mean (SD) | 113.4 (44.9) | 93.8 (50.2) | 116.1 (48.4) | 0.14 |
| Referral timeliness | ||||
| time from positive test to referral (days), mean (SD) | 1.2 (1.3) | 1.1 (1.3) | 0.9 (1.3) | 0.66 |
| time from symptom onset to referral (days), mean (SD) | 2.9 (1.4) | 2.3 (1.4) | 2.6 (1.6) | 0.026 |
| time from symptom onset to 1st dose (days), mean (SD) | - | 4 (1.4) | 4.4 (1.7) | 0.09 |
a
Calculated as weight in kg divided by height in m2.